Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc..
Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, we documented that fecal Akkermansia muciniphila (Akk) was associated with clinical benefit of ICI in patients with NSCLC or kidney cancer. In the current study, we performed shotgun-metagenomics-based microbiome profiling in a large cohort of patients with advanced NSCLC (n = 338) treated with first- or second-line ICIs to prospectively validate the predictive value of fecal Akk. Baseline stool Akk was associated with increased objective response rates and overall survival in multivariate analyses, independent of PD-L1 expression, antibiotics, and performance status. Intestinal Akk was accompanied by a richer commensalism, including Eubacterium hallii and Bifidobacterium adolescentis, and a more inflamed tumor microenvironment in a subset of patients. However, antibiotic use (20% of cases) coincided with a relative dominance of Akk above 4.8% accompanied with the genus Clostridium, both associated with resistance to ICI. Our study shows significant differences in relative abundance of Akk that may represent potential biomarkers to refine patient stratification in future studies.
| Errataetall: |
CommentIn: Cell Rep Med. 2022 May 17;3(5):100642. - PMID 35584634 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Nature medicine - 28(2022), 2 vom: 03. Feb., Seite 315-324 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
B7-H1 Antigen |
|---|
| Anmerkungen: |
Date Completed 26.04.2022 Date Revised 26.10.2022 published: Print-Electronic CommentIn: Cell Rep Med. 2022 May 17;3(5):100642. - PMID 35584634 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41591-021-01655-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336483643 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336483643 | ||
| 003 | DE-627 | ||
| 005 | 20231225232242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41591-021-01655-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1121.xml |
| 035 | |a (DE-627)NLM336483643 | ||
| 035 | |a (NLM)35115705 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Derosa, Lisa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.04.2022 | ||
| 500 | |a Date Revised 26.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Cell Rep Med. 2022 May 17;3(5):100642. - PMID 35584634 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer Nature America, Inc. | ||
| 520 | |a Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, we documented that fecal Akkermansia muciniphila (Akk) was associated with clinical benefit of ICI in patients with NSCLC or kidney cancer. In the current study, we performed shotgun-metagenomics-based microbiome profiling in a large cohort of patients with advanced NSCLC (n = 338) treated with first- or second-line ICIs to prospectively validate the predictive value of fecal Akk. Baseline stool Akk was associated with increased objective response rates and overall survival in multivariate analyses, independent of PD-L1 expression, antibiotics, and performance status. Intestinal Akk was accompanied by a richer commensalism, including Eubacterium hallii and Bifidobacterium adolescentis, and a more inflamed tumor microenvironment in a subset of patients. However, antibiotic use (20% of cases) coincided with a relative dominance of Akk above 4.8% accompanied with the genus Clostridium, both associated with resistance to ICI. Our study shows significant differences in relative abundance of Akk that may represent potential biomarkers to refine patient stratification in future studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a Programmed Cell Death 1 Receptor |2 NLM | |
| 700 | 1 | |a Routy, Bertrand |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Andrew Maltez |e verfasserin |4 aut | |
| 700 | 1 | |a Iebba, Valerio |e verfasserin |4 aut | |
| 700 | 1 | |a Zalcman, Gerard |e verfasserin |4 aut | |
| 700 | 1 | |a Friard, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a Mazieres, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Audigier-Valette, Clarisse |e verfasserin |4 aut | |
| 700 | 1 | |a Moro-Sibilot, Denis |e verfasserin |4 aut | |
| 700 | 1 | |a Goldwasser, François |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Carolina Alves Costa |e verfasserin |4 aut | |
| 700 | 1 | |a Terrisse, Safae |e verfasserin |4 aut | |
| 700 | 1 | |a Bonvalet, Melodie |e verfasserin |4 aut | |
| 700 | 1 | |a Scherpereel, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Pegliasco, Hervé |e verfasserin |4 aut | |
| 700 | 1 | |a Richard, Corentin |e verfasserin |4 aut | |
| 700 | 1 | |a Ghiringhelli, François |e verfasserin |4 aut | |
| 700 | 1 | |a Elkrief, Arielle |e verfasserin |4 aut | |
| 700 | 1 | |a Desilets, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Blanc-Durand, Felix |e verfasserin |4 aut | |
| 700 | 1 | |a Cumbo, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Blanco, Aitor |e verfasserin |4 aut | |
| 700 | 1 | |a Boidot, Romain |e verfasserin |4 aut | |
| 700 | 1 | |a Chevrier, Sandy |e verfasserin |4 aut | |
| 700 | 1 | |a Daillère, Romain |e verfasserin |4 aut | |
| 700 | 1 | |a Kroemer, Guido |e verfasserin |4 aut | |
| 700 | 1 | |a Alla, Laurie |e verfasserin |4 aut | |
| 700 | 1 | |a Pons, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Le Chatelier, Emmanuelle |e verfasserin |4 aut | |
| 700 | 1 | |a Galleron, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Roume, Hugo |e verfasserin |4 aut | |
| 700 | 1 | |a Dubuisson, Agathe |e verfasserin |4 aut | |
| 700 | 1 | |a Bouchard, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Messaoudene, Meriem |e verfasserin |4 aut | |
| 700 | 1 | |a Drubay, Damien |e verfasserin |4 aut | |
| 700 | 1 | |a Deutsch, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Barlesi, Fabrice |e verfasserin |4 aut | |
| 700 | 1 | |a Planchard, David |e verfasserin |4 aut | |
| 700 | 1 | |a Segata, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez, Stéphanie |e verfasserin |4 aut | |
| 700 | 1 | |a Zitvogel, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Soria, Jean-Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Besse, Benjamin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d 1995 |g 28(2022), 2 vom: 03. Feb., Seite 315-324 |w (DE-627)NLM074659804 |x 1546-170X |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:2 |g day:03 |g month:02 |g pages:315-324 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41591-021-01655-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 2 |b 03 |c 02 |h 315-324 | ||